This Project Grant award from the National Cancer Institute (NCI), under the Cancer Treatment Research program (CFDA 93.395), is supporting the development of CM-HZ01 as a non-alpha-IL2 therapeutic for the treatment of metastatic melanoma. Celdara Medical, LLC, a biotechnology company, is the awardee and will conduct the research and development efforts. The total funding amount is $1,024,967.00, with a project period from January 1, 2025, to December 31, 2026. The goal is to advance CM-HZ01, an IL-2 super-agonist, to an Investigational New Drug (IND) application for the treatment of metastatic melanoma, a deadly form of skin cancer with limited effective treatment options. This research aims to develop a best-in-class therapeutic that can preferentially promote the expansion of CD8 effector T-cells and improve anti-tumor activity, addressing the challenge of generating effective immunotherapies without substantial toxicity.
Generated 1/28/25, 9:37 AM